WallStreetZenWallStreetZen

NYSEMKT: ARMP
Armata Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ARMP

Based on 2 analysts offering 12 month price targets for Armata Pharmaceuticals Inc

Min Forecast
$15.00+84.73%
Avg Forecast
$15.00+84.73%
Max Forecast
$15.00+84.73%

Should I buy or sell ARMP stock?

Based on 2 analysts offering ratings for Armata Pharmaceuticals Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ARMP's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates ARMP as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their ARMP stock forecasts and price targets.

ARMP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-02-23
lockedlocked$00.00+00.00%2026-01-05

1 of 1

Forecast return on equity

Is ARMP forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is ARMP forecast to generate an efficient return on assets?

Company
N/A
Industry
29.41%

ARMP earnings per share forecast

What is ARMP's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.17
Avg 2 year Forecast
-$0.95
Avg 3 year Forecast
-$0.97

ARMP revenue forecast

What is ARMP's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

ARMP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ARMP$8.12$15.00+84.73%Strong Buy
ELDN$3.87N/AN/A
SRZN$26.16$42.00+60.55%Strong Buy
NAGE$3.84$10.50+173.44%Strong Buy
FATE$2.63$7.00+166.16%Buy
View Top Biotech Stocks

Armata Pharmaceuticals Stock Forecast FAQ

Is Armata Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NYSEMKT: ARMP) stock is to Strong Buy ARMP stock.

Out of 2 analysts, 1 (50%) are recommending ARMP as a Strong Buy, 1 (50%) are recommending ARMP as a Buy, 0 (0%) are recommending ARMP as a Hold, 0 (0%) are recommending ARMP as a Sell, and 0 (0%) are recommending ARMP as a Strong Sell.

If you're new to stock investing, here's how to buy Armata Pharmaceuticals stock.

What is ARMP's earnings growth forecast for 2026-2028?

(NYSEMKT: ARMP) Armata Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.82%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.29%.

Armata Pharmaceuticals's earnings in 2026 is -$282,614,000.On average, 3 Wall Street analysts forecast ARMP's earnings for 2026 to be -$43,061,780, with the lowest ARMP earnings forecast at -$41,373,083, and the highest ARMP earnings forecast at -$44,328,303. On average, 3 Wall Street analysts forecast ARMP's earnings for 2027 to be -$34,823,874, with the lowest ARMP earnings forecast at -$33,458,232, and the highest ARMP earnings forecast at -$35,848,106.

In 2028, ARMP is forecast to generate -$35,572,775 in earnings, with the lowest earnings forecast at -$34,177,764 and the highest earnings forecast at -$36,619,033.

What is ARMP's revenue growth forecast for 2026-2028?

(NYSEMKT: ARMP) Armata Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.77%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.86%.

Armata Pharmaceuticals's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast ARMP's revenue for 2026 to be $0, with the lowest ARMP revenue forecast at $0, and the highest ARMP revenue forecast at $0. On average, 3 Wall Street analysts forecast ARMP's revenue for 2027 to be $0, with the lowest ARMP revenue forecast at $0, and the highest ARMP revenue forecast at $0.

In 2028, ARMP is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ARMP's forecast return on assets (ROA) for 2026-2029?

(NYSEMKT: ARMP) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 29.41%.

What is ARMP's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ARMP price target, the average ARMP price target is $15.00, with the highest ARMP stock price forecast at $15.00 and the lowest ARMP stock price forecast at $15.00.

On average, Wall Street analysts predict that Armata Pharmaceuticals's share price could reach $15.00 by Feb 23, 2027. The average Armata Pharmaceuticals stock price prediction forecasts a potential upside of 84.73% from the current ARMP share price of $8.12.

What is ARMP's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSEMKT: ARMP) Armata Pharmaceuticals's current Earnings Per Share (EPS) is -$7.78. On average, analysts forecast that ARMP's EPS will be -$1.17 for 2026, with the lowest EPS forecast at -$1.13, and the highest EPS forecast at -$1.21. On average, analysts forecast that ARMP's EPS will be -$0.95 for 2027, with the lowest EPS forecast at -$0.91, and the highest EPS forecast at -$0.98. In 2028, ARMP's EPS is forecast to hit -$0.97 (min: -$0.93, max: -$1.00).

What is ARMP's forecast return on equity (ROE) for 2026-2029?

(NYSEMKT: ARMP) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.